Data & Analytics
Pharmacovigilance Software Overview
Comprehensive Guide to FAERS Data
Guide to GVP Module IX
The RxView Blog
How to Replicate a Clinical Meta-Analysis Study in Evidex
Busy News Week for Pharmacovigilance Software
Why Has Pharmacovigilance Software Lagged Behind Other Industries?
When is the Right Time to implement Signal Management Software for Pharmacovigilance?
FAERS Data Optimization & Deduplication in Evidex Gets Even Faster
3 Thoughts on the 2019 DIA-PVRMS Conference
Top 5 Blog Posts in 2018
Videos - The Evolution of Pharmacovigilance Software
The Evolution of Pharmacovigilance Software
Quality Requirements in GVP Module IX for Signal Management
Signal Prioritization and Assessment in GVP Module IX for Signal Management
Signal Validation in GVP Module IX for Signal Management
The Signal Detection Process in GVP Module IX for Signal Management
An Introduction to GVP Module IX for Signal Management
A New Option for Safety Signal Management and Pharmacovigilance Workflow
Are Social Media Data used in Pharmacovigilance Biased?
Reducing the Noise from Social Media for Pharmacovigilance
What's Driving Pharmacovigilance Technology Acquisition?
The Value and Validity of Social Media Monitoring in Pharmacovigilance
Depression as a Drug Side-Effect: A Quick FAERS Analysis
Can Modern Analytics be Forced into Traditional Pharmacovigilance Workflow Tools?
Advera Health's Commitment to FAERS Data Quality and Turn Around Time
Social Media Monitoring for Pharmacovigilance and Drug Safety
2018- The Year of Next Gen Drug Safety and Pharmacovigilance 2.0
Analysis of a FDA Safety Signal: DPP-4's and Rhabdomyolysis
Evidex Goes Global - VigiBase Drug Safety Data Access
An Analysis of Adverse Events Associated with Endothelin Receptor Antagonists (ERAs) using FAERS
Santa Rosa Wildfires - A Very Tough Week at Advera Health
FAERS Thee Well - Drug Safety Excitement with FDA Dashboard
How Pharmacovigilance Departments Can Work Smarter, Act Bigger
Case Studies: Signal Detection Utilizing FDA Adverse Event Reporting System (FAERS) Data
What happens when a Safety Signal contradicts Clinical Trial data?
FDA Releases Q1 2017 Drug Safety Watch List: It’s Boring and That’s Good
Canada’s March Toward Mandatory Reporting of Adverse Events by Providers
Failure to Warn: The Week in Drug Safety News
Post-Marketing Drug Safety and Pharmacovigilance Is Now More Important Than Ever
Pharmacovigilance 2.0 – Let Freedom Ring in Philadelphia!
2016 FDA Adverse Event Reporting System (FAERS) Data: An Infographic
Using FAERS to Determine Medical Costs – a Payer Perspective
Calculating the Reporting Rate of Adverse Events in FAERS – A New Methodology
Efficacy vs. Effectiveness - The Role of Pharmacovigilance
A Big Data Stumble in Healthcare
Increasing Pressure for Increased Pharmacovgilance Capabilities
Drug Safety Progressives – The Rise of the Pharmacovigilante
Working Toward a Cure: The Foundation for Sarcoidosis Research
Why Does Adverse Event Reporting to FAERS Continue to Accelerate?
Guest Post: BBK Talks #BigData with Advera Health Analytics
Chronic Underreporting of Clinical Trials
A Crystal Ball for FDA Action: How we Validated RxSignal
Watson Health is the Ultimate Data Parasite
RxSignal 3.0 - Predicting FDA Label Changes
Should Adverse Drug Event Reporting by Healthcare Providers be Mandatory?
FAERS - Myths vs. Realities
OpenFDA – the Good, the Bad, and the Ugly
FDA Releases Updated Drug Safety Data – Announces OpenFDA… Now hold your applause
How Are Post-Approval Adverse Drug Event Data Obtained?
427 Mendocino Avenue, Suite 150, Santa Rosa CA 95401
Copyright 2019 | Advera Health Analytics, Inc.